Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 J&J FY Revenues up 14% | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

J&J FY Revenues up 14%

Janssen COVID-19 Vaccine contributes $1.6 billion in the quarter and $2.4 billion for the year.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson
4Q Revenues: $24.8 billion (+10%)
4Q Earnings: $4.7 billion (+173%)
FY Revenues: $93.8 billion (+14%)  
FY Earnings: $20.9 billion (+42%)
Comments: Pharmaceutical sales were $52.1 billion, up 14% for the year, driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), for the treatment of a number of immune- mediated inflammatory diseases, TREMFYA (guselkumab), for the treatment of moderate to severe plaque psoriasis, and active psoriatic arthritis, ERLEADA (apalutamide), for the treatment of prostate cancer, and INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia. Also contributing to growth were sales of the Janssen COVID-19 Vaccine (Ad26.COV2.S), which were $1.6 billion in the quarter and $2.4 billion for the year. This growth was partially offset by declines in sales of REMICADE (infliximab), a treatment of a number of immune- mediated inflammatory diseases. Sales were down 15% in the quarter to $764 million and down 15% for the year to $3.2 billion.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters